



Workshop B4 – MCC Clinical Trial Performance Metrics:

An Industry-wide Effort to Develop and Implement Standardized Performance Metrics to Drive Time, Cost and Quality & Enhance Partnership Performance ... UPDATE!

Cory Gutterman
Associate Director, GPRD Outsourcing
ABBOTT LABORATORIES
Chair, MCC Clinical Trial Metrics SC

Mike Minor
SVP, Proposals and Business Information
ICON CLINICAL RESEARCH

Guy Mascaro
President
MCC

Jennifer Holmes
Sourcing Relationship Manager,
Global Medical Research and Development
ELI LILLY and COMPANY

IIR Partnerships in Clinical Trials ♦ April 12, 2010 ♦ Orlando, FL



Part I: Overview of the Metrics Champion Consortium (MCC) Clinical Trial Performance Metrics Initiative

BREAK

Part II: Clinical Trial Performance Metrics: Workgroup Breakout Session

Part III: Incorporating Performance Metrics into CRO contracts

Part IV: Clinical Trial Performance Metrics: Feedback/Discussion Session

Part V: Q&A Panel Discussion



Part I: Overview of the MCC Clinical Trial Performance Metrics Initiative



The Metrics Champion Consortium (MCC) is a not-for-profit organization comprised of biotechnology, pharmaceutical and service provider organizations who work collaboratively to develop and implement standardized performance metrics aimed at improving the efficiency and effectiveness of managing and tracking resources needed to successfully run clinical trials.

94% of Sponsors reported that demand from their organizations for performance metrics was growing or rapidly growing

Exhibit 1





Exhibit 2

My company effectively uses performance metrics to IMPROVE RELATIONSHIPS with CROs. (sponsor responses)



62% of Sponsors reported that they did not routinely use performance metrics to help *improve relationships* with CROs

54% of Sponsors reported that they did not routinely use performance metrics to *improve productivity* with CROs

Exhibit 3

My company effectively uses performance metrics to IMPROVE PRODUCTIVITY with CROs. (sponsor responses)






Exhibit 4

My company has well defined service provider performance metrics that are clearly understood internally and by our service providers (sponsor responses)





9% of Sponsors reported having well-defined, clearly understood performance metrics currently in place

83% of CROs reported that the demand for performance metrics was growing (50%) or rapidly growing (33%) among Sponsor companies



0% CROs reported that Sponsor companies request and review performance metrics to take effective action with them







MCC Clinical Trial Performance Metrics





Clinical Trial Metrics Steering Committee (2008-2010)

- Cory Gutterman / Abbott
- Ed Cannon / AstraZeneca
- Jennifer Holmes & Holly Hankins / Eli Lilly
- Colleen McCoy / Genentech
- Keith Dorricott / i3
- Pam Howard / ICON Clinical Research
- Kathe Balinski / Mederex
- Magaly Woolard / Merck
- April Davis / Perceptive Informatics
- Lorraine Waring / Pfizer
- Bryan Haas / PPD

Proposed Metric - Qualities

- Well defined
- Be measurable
- Be high level – but allow for further analysis
- Leading Indicator - Lagging Indicator
- Provide a benefit to Sponsor and Service Provider
- Add Value
- Relationship metrics will be added in future version

Cycle Time (CT): Measures how long it takes to complete a task (i.e. # of days)

Timeliness (T): Measures whether a milestone was achieved on-time (i.e. within agreed upon turnaround time)

Quality (Q): Measures the number of errors in completing a task or completion of quality-related activity

Efficiency / Cost (E): Measures the resources required to complete a task


Metric #	Metric Type	Metric Title	Category	Metric Indicator	Part of Study
Definition		Formula / Example		Reporting Detail	
				Unit of Measure	
Business Driver(s) / Benefit Statement		Additional Analysis on a "for cause" basis		Reporting Frequency	Target

Companion Metrics

Example: MCC Clinical Trial Performance Metrics v 1.0

Metric #	Metric Type	Metric Title	Category	Metric Indicator	Part of Study
7	CT	Protocol approval to first site activated	Site Selection and Activation	LEADING Indicator	Study Startup
Definition (see Wiki for detailed definitions)		Formula / Example		Reporting Detail	
Number of calendar days from the date the final approved protocol is released to the Project Team to the date of first site activated (trial level, country level) See MCC Wiki for definitions		Formula: Duration to first site activated = X - Y, where X is Date of First Site Activated; and Y is Date of Protocol Approval Example: Protocol Approved April 13 and First Site Activated August 1; [Aug 1 -- Apr 13] = 109 calendar days		By trial level By country Unit of Measure Calendar days	
Business Driver(s) / Benefit Statement		Additional Analysis on a "for cause" basis		Reporting Frequency	Target
Leading indicator for protocol issues, site performance, CRO performance, regulatory approvals, etc. Increased understanding of geographical differences in site activation. The adherence to plan for site activation is a leading indicator for site activation performance. Key project management indicator of adherence to project plan.		Analysis of reasons for delay include: - timelines for ethics approvals/ signed site agreement and regulatory approval - monitoring resource availability - protocol amendments		Bi monthly during site selection phase	+/- 14 calendar days per contract, by geography (Green) Within 14 – 28 calendar days per contract by geography (Yellow) > 28 calendar days per contract by geography (Red)
Companion Metrics		Metric # 5 - Site Assessment Quality Score, Metric #6			

This List



Clinical Trial Initiative

MCC Home
Members
Central Lab Initiative
ECG Initiative
Clinical Trial Initiative
Imaging Initiative
Board of Directors
Industry Advisory Board
Admin
Site Actions

Metrics Champion Consortium > Clinical Trial Initiative > MCC Clinical Trial Performance Metrics Wiki

MCC Clinical Trial Performance Metrics Wiki

View All Site Content

Documents

- Steering Committee
- Biometrics WG
- Business Ops / Finance WG
- Clinical Ops WG
- Drug Supply WG
- Project Mgmt WG
- Quality Assurance WG
- Beta Metrics Feedback
- Process Improvement WG
- MCC Clinical Trial Performance Metrics Wiki

Lists

- Clinical Trial Initiative WG

Discussions


- Steering Committee Discussion Area
- WG Discussion Area

Sites


People and Groups

Type	Name	Modified By	Modified	Created By	Created
	Benchmarking	Jeanne Green	2/24/2010 3:59 PM	Jeanne Green	2/24/2010 3:34 PM
	Country Regulatory Package	Gary Urban	3/25/2010 5:25 PM	Gary Urban	3/25/2010 5:25 PM
	CRA	MCC Administrator	4/2/2010 1:03 PM	MCC Administrator	2/4/2010 2:11 PM
	CRF (Case Report Form)	MCC Administrator	4/2/2010 1:03 PM	MCC Administrator	2/4/2010 2:08 PM
	Critical Audit Findings	Yvonne Baran	3/31/2010 11:53 AM	MCC Administrator	3/31/2010 11:28 AM
	CSR (Clinical Study Report)	MCC Administrator	4/2/2010 3:04 PM	MCC Administrator	4/2/2010 3:04 PM
	Cycle Time (CT) Metric	MCC Administrator	2/4/2010 3:51 PM	MCC Administrator	2/4/2010 3:51 PM
	Dashboard	Jeanne Green	2/24/2010 3:44 PM	Jeanne Green	2/24/2010 3:36 PM
	DBL (Database Lock)	Gary Urban	3/25/2010 5:23 PM	Jeanne Green	2/24/2010 3:31 PM
	EDC	Jeanne Green	2/24/2010 3:46 PM	MCC Administrator	2/4/2010 2:35 PM
	Enrollment	Gary Urban	2/25/2010 10:46 AM	Jeanne Green	2/24/2010 3:32 PM
	Final Approved Protocol	MCC Administrator	2/19/2010 2:38 PM	MCC Administrator	2/19/2010 2:12 PM
	For Cause Analysis	Jeanne Green	2/24/2010 3:51 PM	Jeanne Green	2/24/2010 3:34 PM
	FPFV (First Patient First Visit)	Jeanne Green	2/24/2010 3:44 PM	MCC Administrator	2/4/2010 2:27 PM
	How To Use This Wiki Library	MCC Administrator	2/4/2010 1:56 PM	MCC Administrator	2/4/2010 1:56 PM
	IP (Investigational Product)	MCC Administrator	3/30/2010 9:42 AM	Gary Urban	3/25/2010 5:20 PM


MCC Clinical Trial Performance Metrics v 1.0




Study Start-up (SSU)



- CT
- T
- Q
- E




- CT
- T
- Q
- E





Process Improvement Work Group








“Not everything that can be counted counts and not everything that counts can be counted.”

Albert Einstein


- Reviewed all MCC Clinical Trial Performance Metrics (beta version) re: value for process improvement
- Conducted focused review of Study Start-up activities:
 - created new quality measures
- Developed guidance paper on “How to Use Metrics”:
 - Using the data for improvement and learning
 - Pitfalls eg.
 - Sub-optimization
 - Reacting to common cause variation
 - Losing sight of the final outcome
 - More is not always better
 - How to collect data and report

Types of MCC Performance Metrics






Example of MCC Patient Screening and Recruitment Companion Metrics



Example of MCC Monitoring Companion Metrics



- Focused on study start up process –

**High Quality
Protocol**

+


**Good Site
Selection**


=

**High Chance of
Successful Trial**



- Concerned that focusing only on cycle-time is likely to sub-optimize
- Defined two new metrics:
 - Protocol Quality
 - Site Selection Quality





Protocol Team answers 7 questions about the thoroughness of addressing:


1. Regulatory requirements/obligations
2. Dosage/formulation
3. Protocol design reflecting clinical practice
4. Study schedule
5. Screening is balanced
6. Procedures is reasonable
7. Protocol-specific equipment and materials availability


Scoring System


<i>Score</i>	<i>Survey Type</i>	<i>Data Source</i>	<i>Protocol Mod</i>
0	Didn't address this question		
1-3	Protocol synopsis & written feedback	Countries/regions only	None
4-6	Near-final protocol & brief interview	Some sites in some countries	Key mods only
7-9	Near-final protocol & extended interview	Some sites in all countries	All mods made
10	Protocol identical to previous. No risk		


- Difficult to measure – but important for success
- Feedback on Protocol Quality metrics very positive:
 - Of 6 teams, 4 rated it as 9 or 10 out of 10 for recommending use to colleagues
 - “I think this tool is extremely helpful and hope that teams will adopt it.”
- Current discussions ongoing on piloting and validating this metric

MCC Plans to Validate Protocol Quality Score










Criteria are weighted and then each site assessed:

1. Proven ability to enroll subjects for this or a similar indication
2. No competing studies that impact this site
3. Appropriate standard of care
4. Investigator with relevant interest, background and experience
5. Experienced staff
6. Good facilities (including physical & electronic infrastructure)
7. Patient population is accessible and protocol appropriate
8. Can meet study start-up timelines within ethical & legal requirements
9. Proven ability to produce high quality data & is responsive to queries (paper or edc)
10. Site uses recruitment and retention plans

Scoring:

1. Team weights the 10 criteria
 - 1 = Least important for success in this protocol
 - 3 = Key to success for this protocol
2. Key Opinion Leader sites can be excluded from the rating
3. Team scores each site as yes or no for each of the criteria
4. Spreadsheet generates % score for each site
5. Overall weighted score is generated
6. This can then be modified by excluding sites
7. Overall weighted score is also calculated per country
8. Aim is to get a high score with the requisite number of sites

Site Assessment Score Can Be a Companion Metric for Other MCC Metrics



MCC Plans to Validate Site Assessment Score



- Difficult to measure – but important for success
- The act of measuring should modify behaviour:
 - Is the team doing what is needed to get the best protocol?
 - Does a site lack skills and need specific training?
 - Have I got enough high quality sites in country X?
- Interest in developing additional Quality Scoring Approach for CRFs and CSRs

This is a paradigm shift for industry and difficult to measure, nevertheless, key to improving overall performance and compliance.

- MCC Board of Directors issued RFP to seek services of experienced metrics database vendor
- MCC is establishing an Alliance Partnership with CMR International, a Thomson Reuters business
- The Alliance Partnership, with the guidance of MCC Members, is developing the database repository reporting platform utilizing Spotfire Analytics software



Spotfire Analytics Demo



- MCC Clinical Trial Performance Metrics (beta version) has been updated to version 1.0, which includes:
 - distinct metrics for paper vs edc processes
 - additional clinical operations metrics
 - key terms defined in online MCC Wiki
 - companion metric designations
 - 2 new quality scoring measurements (Protocol development and site assessments)
 - MCC Metrics Guidance Paper
- MCC – CMR International Alliance Partnership will provide MCC Sponsor & CRO Members the opportunity to participate in MCC Member Blinded Metrics Database



Part II: Breakout Groups



1. What do you see as the benefits to your organization, sponsor/CRO partnerships and the industry of utilizing MCC performance metrics to support/drive change in the drug development process?
2. Who are the stakeholders in your organization that can support the effective implementation and utilization of performance metrics?
3. What are the challenges your organization faces in effective implementation and utilization of performance metrics?
 - a. Organizational structure?
 - b. Culture?
 - c. Technology?
 - d. Training?
 - e. Resources?



Part III: Incorporating Performance Metrics into CRO contracts

Mike Minor
SVP, Proposals and Business Information
ICON CLINICAL RESEARCH



- By company approach to metrics
 - Frequently requested
 - Used at the project and functional service level
 - Internal tool with strategy differences at the product level
 - Seldom consistent from project to project
 - Often confusing
 - Mostly misinterpreted
 - Not appropriate for benchmarking

- Well defined including collection, reporting and analysis mechanisms
- Interpretable within and across participants
- Relevant to work performed
- Focused by process and function
- Facilitates cross-industry benchmarking

- Centralized control introduces metrics into all projects
- May be defined once in MSAs
- Discussed in governance (regular discussion promotes better understanding)
- Adopted in working practices (process improvements)
- Adjunct to older internal metrics (but more focused)
- Assists with alignment of resources and goals
 - Timelines, quality gates, costs and reduces COs

MCC Metrics in the Outsourcing Continuum

**RFI ⇒ Proposal ⇒ Contract ⇒
Operations
{ Repeat }**

- Distinguish operations based on a set of industry standards for timeliness and quality
 - Present tangible benefits to partner
 - Show where/how efficiencies have been achieved
- Set expectations for future engagements based on industry benchmarks
 - Reinforces marketing messaging with objective measures


- Use internal benchmarks to identify risk potential in requested support
 - Unrealistic cycle times, inefficiencies in design, or inappropriate resource support levels and unattainable timelines spell trouble
- Propose better solutions based on benchmarked performance

- Target Metrics add definition to scope
 - Cycles and turnaround times
 - Quality gates and rejection rates
- Better comprehension of deliverables expectations
 - Yields more accurate costs
 - Fewer out of scopes and over budget situations
- Define expectations for metrics reporting and output (performance) review

- Commit to essential metrics
- Adopt business metrics as well as ops metrics to understand cost impact of both business and operational process change
- Provide standard set of measures to compare within company and among partner performance
- Promote relationship management through metrics maintenance in governance
 - Standardization of reporting and performance appraisal leads to open dialog and process improvement
- Provide a platform for benchmarking and process improvement

- Helps identify where process change is needed to improve outcome

Time




Task execution
Metric creation
Reporting

Cost



Resource use
B-I-C process
B-I-C tools

Quality



Tolerance
TAT
Risk Management

- Industry-wide definitions make reporting simpler and more efficient
- Metrics analysis helps with root cause determinations for failures
- Benchmarking helps **everyone** do better
- Documented solid performance encourages repeat performances
- Governance promotes awareness
- Non-fit risks may be identified early

- Application of same metrics to **internal and external** process helps to evaluate process improvement opportunities
- Benchmark metrics can be used to score clients
 - Turn around or response times
 - DSOs
 - Helps identify potentially unrealistic expectations in evaluation of contracting risks

Use industry-wide metrics to answer RFIs or drive behavior change:

Sponsor RFI Questionnaire:

- “Based upon your expertise, comment on what works well with/for other clients, but has not worked/been implemented with us. Where do you feel we can improve / realize efficiencies?”

- Serves as foundation for operations-level win-win reviews
- Promotes constructive dialog leading to performance improvement
 - Move from provider to partner status
 - Mutually agreed practices or revised and updated SOPs
- Consideration of targets leads to better risk management strategies



Case Study #1

Labs Metrics: Getting Started

- Identify essential metrics from MCC list
- Review and agree definitions
- Test sources of data
- Refine reports and set frequencies for delivery
- Plan for meetings to discuss results
- Establish contracted obligation
- Iterative process so expect and accept change
- Be alert for divergence

Metric	Category	Metric Title	Definition [^]	Reason for changes in v1.1
4	Data Cleaning	Percentage of queries from central laboratory to site based upon requisitions received	<p>Minimum: The number of queries generated between the central laboratory and the sites, compared to the number of requisitions received by a central laboratory.</p> <p>Additional analysis on a “for cause” basis:</p> <p>a. The number of queries generated between the central laboratory and the site, compared to the number of requisitions received for a site, protocol, sponsor, and central laboratory by business unit.</p> <p>b. The reasons which resulted in these calls by central laboratory defined by site, protocol, sponsor, and central laboratory by business unit.</p>	This metric was refined to reflect the organization’s overall ability and track record in query levels across all their studies. Sponsor level and study level are optional additional metrics.
5	Data Cleaning	Average turnaround for resolution of queries from central laboratory to site	<p>Minimum: Average time required for resolution of queries from central laboratory to site based on the requisitions received by a central laboratory.</p> <p>Additional analysis on a “for cause” basis: The amount of time required to resolve these queries by reason for a site, protocol, sponsor, and central laboratory by business unit.</p>	This metric captures the time to resolve the queries by the lab across all their studies. Sponsor level and study level are optional additional metrics.
6	Site Support Services	Percentage of queries from site to central laboratory based upon requisitions received with average turnaround time	<p>Minimum: The number of queries generated between the site and the central laboratory, compared to the number of requisitions received for a sponsor and central laboratory, and the average time to resolution</p> <p>Additional analysis on a “for cause” basis: The number and type of queries generated between the site and the central laboratory, compared to the number of requisitions received by protocol.</p>	Type of query was added to this metric as a clarifier for the reasons why the queries are occurring. Title, formula, and target were clarified to match the benefit statement.

ICON Central Laboratories METRICS

Print Date:	<p>ICON Central Laboratories (ICL) have begun the initiative of providing quarterly metrics based on Central Laboratory Metrics Consortium's Guidelines. We, in partnership with our Clients, are now providing the 5 most important of the Standard MCC Metrics to evaluate study success.</p> <p>ICL has committed to continuing to deliver those Standard MCC Metrics that are deemed useful for your use in the future.</p>
Report Description:	
2009-Q1	

Metrics Report for Sponsor A 2009-Q1


Metric	Category	Laboratory Metrics Champions Definition (v2.0)	ICL Definition (per study/ per Quarter)	Unit of Measure	Target
4	Data Cleaning	The number of queries generated between the central laboratory and the sites, compared to the number of requisitions received by a central laboratory.	The number of visits that needed an outgoing query to sites, compared to the number of total visits received by ICL.	Total N and Percentage	<20%
6	Site Support Services	The number of queries generated between the sites and central laboratory, compared to the number of requisitions received for a sponsor and a central laboratory.	The number of incoming queries generated by sites, compared to the number of total visits received by ICL.	Total N and Percentage	>95%
8	Safety	Percentage of panics that had both 1st attempt made and were successfully communicated to the sites within the defined turnaround times overall by sponsor and central laboratory.	Percentage of call lists that contained at least one panic value that had an action and have been successfully communicated to the site. Successful communication is defined by either an email reply, signed fax, or repeated value telephone confirmation. (Note that values are not limited to business days or hours and therefore Sunday data is represented in totals)	Total N and Percentage	>95%

Total Number of Panic Calls




Project Numbers Deleted

% Panics 1st action within 24 hours




Project Numbers Deleted

% of Panics SuccessCommun w/in 24 hrs



Discuss: Leverage the Sourcing Strategy




- Governance active in deciding which metrics will be used to measure health of relationship
- Contracted metrics collected at operations level and reported up to operational and business leadership
- Analysis of trends is formalized as agenda in Governance meetings
- Executive Leadership in Governance drives transformational change into partnership

- Not all metrics can be reported without systematic or programmatic change
 - Assess cost/benefit
 - Accept? redefinition è divergence
- Understand the root causes for failures when considering performance
 - e.g., ACP definition for completed lab contact for panic value is different from industry
- Use program to improve process
 - We have instituted Sunday staffing in ICL for panic reports
 - Does not improve metric but improves outcome for patient

Case Study #2


Functional Services Contracted Metrics Driven Process Improvement



Source: Thomson CenterWatch 2005 Survey of 612 Investigative Sites in the U.S.

- Observation
 - Regulatory packages approval is rate limiting to start-up
- Contracted Essential Metrics
 - Cycle time for approval
 - Rejection rate

- Functional Services
- Approval rate target
- Turnaround target
- Continuous improvement incentive
- Monthly metrics reporting
- Governance Board
 - Monthly functional review
 - Quarterly management review



- Internal and external benchmarking identified process improvement opportunities
- Significant improvement in cycle times and lowered rejection rates resulted
 - For Sponsor – faster start-up
- Sustained quality improvement achieved by CRO
 - Reduced oversight (and headcount) required by Sponsor
 - Incentives achieved by CRO
- Expanded assignment of work to CRO

Outlook for use of MCC Clinical Metrics

- Overall, the industry has to become more efficient
 - Drowning in data: starved for information
- To improve efficiency, we must characterize and benchmark the baseline
- Industry must pull standardized metrics into its contracting tool kit
 - Similar to TORO, TOM, etc.
- Business metrics will be valuable when analyzed in tandem with operational metrics
 - e.g., Metric #27 (change orders) as related to operational process (protocol finalization before/after proposal, feasibility before/after proposal, etc)

- Cross Industry collaboration has improved MCC beta version
 - Definitions and reporting
- Centralized metrics reporting will help the industry become more efficient by identifying better practices
- Best practices should be shared to improve industry performance
- MCC provides a new level of information sharing for the Industry

Questions?



Part IV: Breakout Group Feedback



1. What do you see as the benefits to your organization, sponsor/CRO partnerships and the industry of utilizing MCC performance metrics to support/drive change in the drug development process?
 - ID Process Improvement targets
 - Common language for contracts
 - ID of new metrics (Q)
 - Decision drivers for future relationships
 - Drive process improvement across projects
 - Start up efficiency
 - ID gaps and issues
 - Share best practices
 - Reduce oversight
 - Real time analysis
 - Facilitates discussions
 - Quantitative / Qualitative
 - Standardization of review

1. What do you see as the benefits to your organization, sponsor/CRO partnerships and the industry of utilizing MCC performance metrics to support/drive change in the drug development process?

Sponsor	CROs
<ul style="list-style-type: none"> • Adoption/Standardization • “Internal market“ to collect metrics • FDA compliance acceptability • Help relationship with common platform • Common language to measure all vendors • Cut through “metrics fog” • Work group dialogue • Improvement in execution A-Z (in – sourced) • No blame • Quality / auditable • Reduce errors / variability <ul style="list-style-type: none"> – before, not after • Benchmarking made easier • Setting industry expectations • Better understanding of what you can get or due 	<ul style="list-style-type: none"> • Consistency • Realistic project management & decrease risk • How performance is evaluated helps motivation • Continuous process improvement <ul style="list-style-type: none"> – fact based, objective criteria – reduces variability • Customer satisfaction • Competitive edge • Showing – yes we can • Better definitions • Standard expectations

2. Who are the stakeholders in your organization that can support the effective implementation and utilization of performance metrics?
 - Senior Mgmt
 - Corporate / regional /local reps
 - VP Clin Ops
 - Finance
 - Procurement / Contracts
 - Clinical directors
 - Therapeutic area head
 - Functional lines
 - Global project manager
 - IT
 - Quality
 - Sites

3. What are the challenges your organization faces in effective implementation and utilization of performance metrics?
 - Senior leadership buy-in
 - Business structure
 - Governing body
 - Increasing expectations for excellence
 - Resistance to change
 - Agreement of definitions
 - CRO want to be unique
 - Varying data sources
 - Utilizing metrics to make decisions
 - Process improvement vs “punishment”

3. What are the challenges your organization faces in effective implementation and utilization of performance metrics?
 - Internal/external factors
 - Infrastructure – IT/Logistics/Technology/Systems
 - Budget
 - Quality metrics can be difficult
 - Communication
 - Multiple providers: agreement on criteria
 - Training
 - ROI - value
 - Procurement vs Ops
 - Big Pharma vs little pharma
 - Number of metrics: core vs too many



Part V: Q&A Panel Discussion

